⌘K
t
On 13 November 2025, Beximco Pharmaceuticals PLC requested an extension from the Bangladesh Securities and Exchange Commission, Dhaka Stock Exchange, and Chittagong Stock Exchange. This request pertains to the submission and publication of its first quarter financial results for the three-month period ended 30 September 2025. A required Board of Directors meeting to approve these results is currently not possible due to an outstanding High Court of Bangladesh case regarding BSEC's proposed appointment of nine additional independent non-executive directors.
| Date | 13 Nov 2025 |
| Time | 16:00:00 |
| Category | Miscellaneous |
| ID | 4773H |
13 November 2025
BEXIMCO PHARMACEUTICALS PLC.
Request of Extension to Publish First Quarter Results for the Three-Month Period Ended 30 September 2025
Beximco Pharmaceuticals PLC. ("the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces that the Company has written to the Bangladesh Securities and Exchange Commission (BSEC), the Dhaka Stock Exchange and the Chittagong Stock Exchange to request an extension to submit and publish its first quarter financial results for the three-month period ended 30 September 2025.
In order to approve the first quarter results for the Company, for the three-month period ended 30 September 2025, a meeting of the Board of Directors is required. This is not possible currently because, in line with the Company's previous announcements, dated 21 March 2025, 21 May 2025 and 15 September 2025, BSEC's proposed appointment of an additional nine independent non-executive directors to the Company's Board of Directors remains outstanding in the High Court of Bangladesh. This also follows a similar requests made by the Company on 27 April 2025 and 27 October 2025, in respect of seeking an extension to publish its Q3 financial results, for the quarter ended 31 March 2025, and financial results for the year ended 30 June 2025 respectively.
As previously announced on 15 September 2025, the Company believes that the High Court's decision on the BSEC Order will not be forthcoming until November 2025. Further announcements will be made as appropriate.
For further information please visit www.beximcopharma.com or enquire to:
|
Beximco Pharma |
|
Mohammad Ali Nawaz, Chief Financial Officer Tel: +880 2 58611001, Ext. 20030
Mohammad Asad Ullah, FCS Executive Director & Company Secretary Tel: +880 2 41060531, Ext. 10140
|
|
SPARK Advisory Partners Limited (Nominated Adviser) Mark Brady / Andrew Emmott Tel: +44 (0)20 3368 3551 / 3555
|
|
SP Angel Corporate Finance LLP (Broker) Matthew Johnson Tel: +44 (0) 20 3470 0470
|
|
FTI Consulting Simon Conway / Sam Purewal Tel: +44 (0)20 3727 1000
|
Notes to Editors
About Beximco Pharmaceuticals PLC.
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.